MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline
MaxCyte (NASDAQ:MXCT) has signed a Strategic Platform License Agreement with Anocca AB for the use of MaxCyte's Flow Electroporation® technology and ExPERT™ platform. The agreement grants Anocca non-exclusive research, clinical, and commercial rights to support their TCR-T cell therapy development.
Under the agreement, MaxCyte will receive annual licensing fees and program-related revenue. The partnership aims to enhance Anocca's cell therapy manufacturing capabilities, particularly for their lead program targeting KRAS-driven advanced pancreatic cancer currently in clinical development. Anocca recently received GMP compliance certification and manufacturing license from Swedish regulators.
MaxCyte (NASDAQ:MXCT) ha firmato un Accordo Strategico di Licenza Piattaforma con Anocca AB per l'utilizzo della tecnologia Flow Electroporation® e della piattaforma ExPERT™ di MaxCyte. L'accordo concede ad Anocca diritti non esclusivi di ricerca, clinici e commerciali per supportare lo sviluppo della loro terapia cellulare TCR-T.
In base all'accordo, MaxCyte riceverà canoni di licenza annuali e ricavi legati ai programmi. La collaborazione mira a potenziare le capacità di produzione di terapie cellulari di Anocca, in particolare per il loro programma principale che punta al cancro pancreatico avanzato guidato da KRAS, attualmente in fase clinica. Anocca ha recentemente ottenuto la certificazione GMP e la licenza di produzione dalle autorità svedesi.
MaxCyte (NASDAQ:MXCT) ha firmado un Acuerdo Estratégico de Licencia de Plataforma con Anocca AB para el uso de la tecnología Flow Electroporation® y la plataforma ExPERT™ de MaxCyte. El acuerdo otorga a Anocca derechos no exclusivos de investigación, clínicos y comerciales para apoyar el desarrollo de su terapia celular TCR-T.
Según el acuerdo, MaxCyte recibirá cuotas de licencia anuales e ingresos relacionados con los programas. La colaboración busca mejorar las capacidades de fabricación de terapias celulares de Anocca, especialmente para su programa principal dirigido al cáncer pancreático avanzado impulsado por KRAS, que actualmente está en desarrollo clínico. Anocca recibió recientemente la certificación de cumplimiento GMP y la licencia de fabricación de los reguladores suecos.
MaxCyte (NASDAQ:MXCT)는 Anocca AB와 MaxCyte의 Flow Electroporation® 기술 및 ExPERT™ 플랫폼 사용을 위한 전략적 플랫폼 라이선스 계약을 체결했습니다. 이 계약은 Anocca에게 TCR-T 세포 치료제 개발을 지원하기 위한 비독점적 연구, 임상 및 상업적 권리를 부여합니다.
계약에 따라 MaxCyte는 연간 라이선스 수수료 및 프로그램 관련 수익을 받게 됩니다. 이번 파트너십은 현재 임상 개발 중인 KRAS 유발 진행성 췌장암을 목표로 하는 Anocca의 주요 프로그램을 포함해 세포 치료제 제조 역량을 강화하는 데 목적이 있습니다. Anocca는 최근 스웨덴 규제 당국으로부터 GMP 준수 인증 및 제조 허가를 받았습니다.
MaxCyte (NASDAQ:MXCT) a signé un accord de licence stratégique de plateforme avec Anocca AB pour l'utilisation de la technologie Flow Electroporation® et de la plateforme ExPERT™ de MaxCyte. Cet accord accorde à Anocca des droits non exclusifs de recherche, cliniques et commerciaux pour soutenir le développement de leur thérapie cellulaire TCR-T.
Dans le cadre de cet accord, MaxCyte recevra des redevances annuelles de licence et des revenus liés aux programmes. Ce partenariat vise à renforcer les capacités de fabrication de thérapies cellulaires d'Anocca, en particulier pour leur programme principal ciblant le cancer du pancréas avancé à mutation KRAS, actuellement en développement clinique. Anocca a récemment obtenu la certification de conformité GMP et la licence de fabrication délivrées par les autorités suédoises.
MaxCyte (NASDAQ:MXCT) hat eine strategische Plattformlizenzvereinbarung mit Anocca AB für die Nutzung der Flow Electroporation®-Technologie und der ExPERT™-Plattform von MaxCyte unterzeichnet. Die Vereinbarung gewährt Anocca nicht-exklusive Forschungs-, klinische und kommerzielle Rechte zur Unterstützung der Entwicklung ihrer TCR-T-Zelltherapie.
Im Rahmen der Vereinbarung wird MaxCyte jährliche Lizenzgebühren und programmbezogene Einnahmen erhalten. Die Partnerschaft zielt darauf ab, die Herstellungsfähigkeiten von Anocca im Bereich der Zelltherapie zu verbessern, insbesondere für ihr führendes Programm, das sich auf KRAS-gesteuerten fortgeschrittenen Bauchspeicheldrüsenkrebs konzentriert und sich derzeit in der klinischen Entwicklung befindet. Anocca hat kürzlich die GMP-Konformitätszertifizierung und die Herstellungslizenz von den schwedischen Aufsichtsbehörden erhalten.
- New strategic licensing agreement provides recurring revenue through annual fees
- Partnership with clinical-stage company expands MaxCyte's presence in cell therapy market
- Agreement includes both clinical and commercial rights, indicating long-term revenue potential
- Non-exclusive licensing agreement limits potential competitive advantages
- Specific financial terms and revenue projections not disclosed
Insights
MaxCyte secures revenue-generating licensing deal with Anocca for TCR-T therapy development using its electroporation platform.
This strategic platform licensing agreement between MaxCyte and Anocca AB represents a significant commercial validation for MaxCyte's Flow Electroporation® technology in the competitive cell therapy manufacturing space. The deal grants Anocca non-exclusive research, clinical and commercial rights to MaxCyte's technology platform in exchange for annual licensing fees and program-related revenue.
The partnership holds particular value as Anocca has already reached important development milestones, including GMP certification from Swedish regulators and advancement of its lead KRAS-targeting pancreatic cancer program into clinical trials. This suggests MaxCyte's technology will be implemented in active development programs with near-term revenue potential rather than merely preclinical applications.
For MaxCyte investors, this agreement follows the company's established business model of securing technology licenses with biotech companies developing next-generation cell therapies. The non-viral gene editing capabilities of MaxCyte's platform are particularly valuable for TCR-T development, as they enable precise cell engineering without viral vector limitations or safety concerns. This positions MaxCyte to capture value from the growing TCR-T therapy segment.
While financial terms weren't disclosed, MaxCyte typically structures these agreements with upfront fees, annual payments that scale with clinical progression, and commercial milestones/royalties. The multi-program nature of Anocca's "deep pipeline" suggests this could become a substantial revenue contributor if programs advance successfully through clinical development.
MaxCyte’s Flow Electroporation® Technology will support non-viral gene editing in the manufacture of Anocca’s TCR-T cell therapies
ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced the signing of a Strategic Platform License Agreement (SPL) with Anocca AB, a leading, clinical stage T-cell immunotherapy company. Anocca AB will deploy MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support the scalable development and manufacturing of its deep pipeline of T-cell receptor engineered T-cell (TCR-T) cell therapies.
Under the SPL, Anocca AB obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte is entitled to receive annual licensing fees and program-related revenue.
“We’re proud to partner with Anocca as they advance the development of TCR-T therapeutics through the clinic,” said Maher Masoud, President and CEO of MaxCyte. “We look forward to supporting Anocca with our globally supported, regulatory-proven platform and technical expertise to accelerate clinical manufacturing and cell engineering processes. Our ExPERT™ platform delivers the robust scalability and flexibility needed to power high-performance, non-viral gene editing workflows across Anocca’s diverse therapeutic pipeline.”
Anocca recently received GMP compliance certification and a manufacturing license from Swedish regulators for its cell therapy production facility, and its lead program, targeting mutant KRAS-driven advanced pancreatic cancer, is in clinical development. With the addition of MaxCyte’s ExPERT™ platform, Anocca acquires a high-quality, scalable, technology platform to enhance its ability to deliver gene-edited cell therapies.
About MaxCyte
At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we’ve been advancing cell engineering, shaping the future of medicine. Learn more at maxcyte.com and follow us on X and LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. Specifically, there is no assurance that MaxCyte will receive additional program-related revenue or other revenue under this SPL.
Risks and uncertainties related to our business are described in greater detail in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 11, 2025, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time, including in our Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 8, 2025. These documents are available through the Investor Menu, Financials section, under “SEC Filings” on the Investors page of our website at http://investors.maxcyte.com. Any forward-looking statements in this press release are based on our current beliefs and opinions on the relevant subject based on information available to us as of the date of such press release, and you should not rely on forward-looking statements as predictions of future events. We undertake no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
US Media Relations
Oak Street Communications
Kristen White
+1 415-608-6060
kristen@oakstreetcommunications.com
FAQ
What is the new licensing agreement between MaxCyte (MXCT) and Anocca AB?
How will MaxCyte (MXCT) generate revenue from the Anocca partnership?
What is Anocca's lead program using MaxCyte's technology?
What regulatory approvals has Anocca received for cell therapy production?
How will MaxCyte's ExPERT platform benefit Anocca's development process?
